Amgen develops MariTide, a monthly weight loss injection potentially maintaining weight loss after treatment.

Amgen is developing a monthly weight loss injection, MariTide, that differs from rival drugs like Wegovy and Zepbound, and may help patients maintain weight loss even after stopping treatment. More data is needed to assess the treatment's competitiveness in the obesity market. Amgen aims to distinguish itself in the crowded field of weight loss drug developers.

March 24, 2024
4 Articles

Further Reading